Capital Analysts LLC’s MaxCyte MXCT Stock Holding History

Capital Analysts LLC’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1K	Hold	1,266	–	–	﹤0.01%	1511
2025 Q4	$2K	Hold	1,266	–	–	﹤0.01%	1417
2025 Q3	$2K	Hold	1,266	–	–	﹤0.01%	1376
2025 Q2	$3K	Hold	1,266	–	–	﹤0.01%	1297
2025 Q1	$3K	Hold	1,266	–	–	﹤0.01%	1288
2024 Q4	$5K	Hold	1,266	–	–	﹤0.01%	1155
2024 Q3	$5K	Hold	1,266	–	–	﹤0.01%	1126
2024 Q2	$5K	Hold	1,266	–	–	﹤0.01%	1046
2024 Q1	$5K	Buy	1,266 +120	+10%	+$563	﹤0.01%	988
2023 Q4	$5K	Hold	1,146	–	–	﹤0.01%	963
2023 Q3	$4K	Hold	1,146	–	–	﹤0.01%	997
2023 Q2	$5K	Hold	1,146	–	–	﹤0.01%	888
2023 Q1	$6K	Hold	1,146	–	–	﹤0.01%	849
2022 Q4	$6K	Hold	1,146	–	–	﹤0.01%	897
2022 Q3	$7K	Buy	+1,146	New	+$6.39K	﹤0.01%	853

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $641M AUM 61.79% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $88.9M AUM

Capital Analysts LLC's MXCT Position: Q1 2026 in Review

Capital Analysts LLC held its MaxCyte (MXCT) position steady in Q1 2026 at 1,266 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1511.

Capital Analysts LLC first reported a position in MXCT in Q3 2022 and has held it in 15 quarters since. The position peaked at $7K in Q3 2022. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

Capital Analysts LLC held 1,266 shares of MaxCyte worth $1K as of Q1 2026.
Capital Analysts LLC left its MaxCyte share count unchanged in Q1 2026.
MaxCyte made up ﹤0.01% of Capital Analysts LLC's portfolio in Q1 2026, its #1511 holding.
Capital Analysts LLC first reported a position in MaxCyte in Q3 2022 and has held it in 15 quarters since.
Capital Analysts LLC's MaxCyte position peaked at $7K in Q3 2022.
130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Capital Analysts LLC's 13F filing for Q1 2026, filed 14 May 2026.